Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Cancer Recurrent 1

Interventions

disitamab vedotin 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ovarian Cancer Recurrent × disitamab vedotin × Clear all
NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡